To overcome these issues and achieve greater specific antibody-mediated killing of tumor Tregs, one approach is to better target surface molecules that are expressed or are elevated only on intratumor Tregs, such as CD25, CTLA-4, GIRT, 4-1BB, OX-40, LAG3, TIGHT, CCR4, and CCR8 [156]. The gene discussed is CTLA4; the disease is neoplasm.